Enfortumab vedotin with pembrolizumab for untreated unresectable or metastatic urothelial cancer when platinum-based chemotherapy is suitable [ID6332]

  • In development
  • GID-TA11233
  • Expected publication date: 

Documents

Documents created during the development process.

Draft guidance

Declaration of interests

Invitation to participate

Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 6332

Topic selection